Table 1.
Characteristics of the study patients according to in-hospital survival status
| Variable | Non-survivors (n = 47) | Survivors (n = 160) | P value |
|---|---|---|---|
| Age | 65 (56–76) | 58 (47–70) | 0.001 |
| Male sex | 27 (57%) | 114 (71%) | 0.079 |
| Body mass index | 25 (23–27) | 26 (23–29) | 0.36 |
| Cardiovascular disease | 19 (40%) | 34 (21%) | 0.012 |
| Diabetes | 12 (26%) | 31(19%) | 0.41 |
| Hypertension | 16 (34%) | 59 (37%) | 0.73 |
| Positive blood culture | 12 (26%) | 45 (28%) | 0.85 |
| Ventilator treatment | 41 (86%) | 114 (71%) | 0.034 |
| Peak creatinine levels in 24 h (μmol/L) | 128 (66–275) | 98 (70–159) | 0.10 |
| Lowest eGFR in 24 h (mg/min) | 38 (19–92) | 68 (39–99) | 0.04 |
| Peak lactate levels in 24 h (mmol/L) | 2.9 (1.6–4.0) | 1.9 (1.1–3.1) | 0.02 |
| Lowest platelet count in 24 h (×109/L) | 126 (87–234) | 148 (88–267) | 0.52 |
| SAPS II score | 51 (39–60) | 41 (31–50) | <0.001 |
| SOFA score | 9 (7–13) | 8 (6–10) | 0.013 |
| 4th gen cTnT on inclusion (μg/L) | 0.04 (0.00–0.21) | 0.02 (0.00–0.09) | 0.14 |
| hs-cTnT on inclusion (μg/L) | 0.054 (0.022–0.227) | 0.036 (0.015–0.111) | 0.047 |
| NT-proBNP on inclusion (pg/mL) | 7,374 (1,308–16,917) | 3,631 (1,256–9,208) | 0.11 |
| 4th gen cTnT at 72 h (μg/L) | 0.03 (0.00–0.20) | 0.01 (0.00–0.08) | 0.11 |
| hs-cTnT at 72 h (μg/L) | 0.054 (0.019–0.224) | 0.035 (0.015–0.093) | 0.054 |
| NT–proBNP at 72 h (pg/mL) | 5,516 (1,364–17,241) | 2,231 (616–6,110) | 0.03 |
eGFR estimated glomerular filtration rate; SAPS II simplified acute physiology score II; SOFA sequential organ failure assessment score; hs-cTnT highly sensitive assay for cardiac troponin T; NT-proBNP N-terminal pro-B type natriuretic peptide